Business
Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
BOSTON, May 07, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent business progress.
About this update from Verastem, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2176,"height":788,"url":"https://media.zenfs.com/en/business-wire.com/95700b3f1b873fa12327713ab92cd911"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/nZ3jMwPZBdMiABHJEybc7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM0OA--/https://media.zenfs.com/en/business-wire.com/95700b3f1b873fa12327713ab92cd911","width":960,"height":348},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/rJzBJ2V4TXpRRaOCVhh6aA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTIzMg--/https://media.zenfs.com/en/business-wire.com/95700b3f1b873fa12327713ab92cd911","width":640,"height":232},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/lLZqjAd8o6Jqdbn.pIRLvw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04NzA-/https://media.zenfs.com/en/business-wire.com/95700b3f1b873fa12327713ab92cd911","width":1200,"height":435}},"lazy":false},{"type":"text","content":"AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $18.7 million","length":63,"tagName":"p","attribs":{}},{"type":"text","content":"Appointed Daniel Lyons as Chief Commercial Officer to lead next phase of commercial growth","length":90,"tagName":"p","attribs":{}},{"type":"text","content":"Initiated Phase 2 registration-directed trials "VS-7375 TARGET-D Clinical Program" in 2L PDAC, 2L/3L NSCLC and 2L+ CRC","length":128,"tagName":"p","attribs":{}},{"type":"text","content":"VS-7375 TARGET-D 101 early data update expected in the first half of 2026; mature data update expected in the second half of 2026","length":129,"tagName":"p","attribs":{}},{"type":"text","content":"Ended Q1 2026 with $181.7 million in cash, cash equivalents and investments; expected cash runway into first half of 2027","length":121,"tagName":"p","attribs":{}},{"type":"text","content":"Company to host a conference call and webcast today at 4:30 p.m. ET","length":67,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, May 07, 2026--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent business progress.","length":307,"tagName":"p"},{"type":"text","content":""As we mark the one-year anniversary of the ...